NOV 16 - 17 2016
Gibco 24 Hours of Stem Cells virtual event
64 275 27538

Stay on the leading edge of stem cell research
There’s still time to check out the 4th annual Gibco™ 24 Hours of Stem Cells™ virtual event. Access all presentations, virtual labs, event certification, resources and more now through November 17, 2017.

Access 24 Hours of Stem Cells on-demand to:

  • Access leading scientific presentations from prominent researchers and thought leader around the world
  • Sharpen your stem cell skills and expertise with virtual training and certifications
  • Gain access to special discounts only available to event attendees*

Experience all of this virtually, from the comfort of anywhere. Register today.


 

What attendees liked about this year's event Take a tour of this year's event

 


If you have additional questions, please contact Chelsie Fritz at chelsie.fritz@thermofisher.com.

*Discount will apply to orders received by Life Technologies no later than May 17 2016 or until promotional supplies are depleted, whichever comes first. Customers can use the discount only once. Limit one per customer. Discount applies to the list price in effect at the time the order is received by Life Technologies. Cannot be combined with other discounts or promotions. Offer void where prohibited, licensed or restricted by federal, state, provincial, or local laws, or regulation, or agency/institutional policy. Other restrictions may apply.

 


Speakers:
  • Professor, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, Germany
  • Professor of Chemical and Biomolecular Engineering, Department of Bioengineering, Director of the Berkeley Stem Cell Center, University of California, Berkeley
  • Stephen A. Wynn Associate Professor of Regenerative Ophthalmology, Director Steven W. Dezii Translational Vision Research Facility, Wynn Institute for Vision Research, Department of Ophthal
  • Senior Research Fellow, Genome Institute of Singapore, Singapore
  • Assistant Professor, Department of Biomedical Engineering and Wisconsin Institute for Discovery- BIONATES, University of Wisconsin-Madison
  • Associate Director, Strategic Collaborations, Biosciences Division, Thermo Fisher Scientific
  • IDIBAPS Researcher, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Spain
  • Postdoctoral Fellow, University of Zurich, Switzerland
  • Director of HipSci Cell Phenotyping Centre for Stem Cells and Regenerative Medicine, King's College London, United Kingdom
  • Professor in Stem Cell Biology, University of Nottingham, United Kingdom
  • PhD candidate, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine
  • Regulatory Consultant, Frey-Vasconcells Consulting, LLC
  • Team Leader, Processing/Manufacturing, Heart Regeneration Program, University of Washington School of Medicine, United States
  • Technical Application Scientist, Cell Biology, Life Sciences Solutions, Thermo Fisher Scientific 赛默飞生命科学产品与服务集团技术支持专家,从事细胞培养、蛋白表达以及转染相关应用的技术支持
  • Instructor in Neurology, MGH Collaborative Center for XDP, Department of Neurology, Massachusetts General Hospital, Harvard Medical School
  • ARC DECRA Fellow, Neurogenetics Research Program, School of Medicine, Faculty of Health Sciences, The University of Adelaide, Australia
  • Associate Director and Group Leader, Thermo Fisher Scientific
  • Independent Group Leader CECAD - Cluster of Excellence, Institute for Neurophysiology & Center for Molecular Medicine (CMMC), University of Cologne, Germany
  • Senior Science Officer, Strategic Infrastructure, California Institute for Regenerative Medicine
  • Chief Executive Officer, Meridigen Biotech Co., Ltd., Taiwan
  • Principal Investigator, The Scripps Research Institute, Center for Regenerative Medicine
  • R&D Scientist, Thermo Fisher Scientific
  • CSO & Executive VP, Stempeutics Research, India
  • Owner, Chief Consultant & Advisor, Hybrid Concepts International
  • Junior Group Leader, Pluripotent Stem Cells and Activation of Endogenous Tissue Programs for Organ Regeneration, The Institute for Bioengineering of Catalonia (IBEC), Spain
  • Development Scientist, CCRM
  • Senior Staff Scientist, Cell Biology, Thermo Fisher Scientific
  • Co-Founder and Chief Scientific Officer, Neurona Therapeutics, Assistant Professor, Adjunct, University of California, San Francisco, United States
  • Director, Molecular Medicine Research Group, Western Sydney University, Australia, Senior Lecturer, School of Medicine, Western Sydney University, Australia Honorary Senior Lecturer, Save S
  • Dean, Professor, Department of Physiology, Keio University School of Medicine, Japan
  • Associate Professor, ARC Future Fellow, Head, Neuroregeneration Research Unit, Centre for Eye Research Australia, University of Melbourne
  • R&D Scientist, Cell Biology, Thermo Fisher Scientific
  • Managing Director, Alliance for Regenerative Medicine
  • Young Investigator, l'institut du thorax INSERM, France
  • Sr. Director Global Regulatory Affairs, Clinical, & Compliance for Life Sciences Solution Group (LSG), Thermo Fisher Scientific
  • Vice President, Technology and Director, BridGE at CCRM, Canada
  • Director, NSW Stem Cell Network, Australia
  • Chairman, Institute for Med. Immunology & Berlin-Brandenburg Center for Regenerative Therapies (BCRT) & Dept. Immunology, Labor Berlin Vivantes, Charité GmbH Charité-Universitätsmedizin, Berl
  • Senior Research Scientist, Regenerative Medicine RxGen, Inc.
  • Partner, Holland & Knight
  • Staff Scientist, Cell Biology, Thermo Fisher Scientific

Show Resources
Agenda

On-demand presentations are pre-recorded and will be available at the open of the event. They can be accessed at any time for your convenience.
 

Click below each speaker's photo to watch their Webcast
Speakers

  • KEYNOTE: Silke Rickert-Sperling, PhD
    Professor, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, Germany
    Biography
      Prof. Dr. Silke Rickert-Sperling holds a doctoral degree in cardiac physiology and studied medicine from 1991 up to her full medical license in 1997. During her education she went from Berlin to New York, San Diego, Chicago, and Rochester. Afterwards she worked as an MD at the German Heart Center of Berlin. In 1999, she began her postdoctoral research at the department of Prof. Dr. Lehrach at the Max Planck Institute for molecular genetics and there she became head of the research group "Cardiovascular Genetics" in 2001. She holds a habilitation in molecular biology and bioinformatics. In 2011, she was honored with a Heisenberg Professorship and became full professor for Cardiovascular Genetics at the Medical Faculty of the Charité in Berlin. She is co-opted professor at the Faculty of Biology, Chemistry and Pharmacy of the Freie Universität Berlin. She leads an interdisciplinary research group (molecular biology and bioinformatics) at the ECRC. As guest scientist, she continues to collaborate with the Max Planck Institute for Molecular Genetics. Her research activities focus on understanding the molecular basis of human cardiovascular disorders, in particular congenital heart malformations and cardiac dysfunction. Using systems biology approaches, she studies cardiac (dys)development and muscle maturation in human and mice. She investigates a broader range of disease-associated genes and epigenetic modulators in the genomic, transcriptomic, and proteomic contexts. She hopes to combine knowledge of molecular etiologies and mechanisms to eventually improve preventive and therapeutic opportunities for patients. She is principal investigator and co-coordinator of various European efforts (HeartRepair, CardioGeNet, and CardioNeT) and principal investigator of the Berlin Institute of Health (BIH). She was a board member of the European Society of Human Genetics and is Fellow of the European Society of Cardiology (ESC) as well as a board member of the ESC Working Group on Development, Anatomy and Pathology.
    • KEYNOTE: David Schaffer, PhD
      Professor of Chemical and Biomolecular Engineering, Department of Bioengineering, Director of the Berkeley Stem Cell Center, University of California, Berkeley
      Biography
        David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at the University of California, Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. He received a B.S. in Chemical Engineering from Stanford University in 1993 and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology in 1998. He then conducted a postdoctoral fellowship at the Salk Institute for Biological Studies before becoming a faculty member at the University of California, Berkeley in 1999. At Berkeley, Dr. Schaffer applies engineering principles to enhance stem cell and gene therapy approaches for neuroregeneration, work that includes novel approaches for molecular engineering and evolution of new viral vectors as well as new technologies to investigate and control stem cell fate decisions. Dr. Schaffer has received an NSF CAREER Award, Office of Naval Research Young Investigator Award, Whitaker Foundation Young Investigator Award, and was named a Technology Review Top 100 Innovator. He was also awarded the American Chemical Society Marvin Johnson Award in 2016, the American Chemical Society BIOT Division Young Investigator Award in 2006, the Biomedical Engineering Society Rita Shaffer Young Investigator Award in 2000, and was inducted into the College of Fellows of the American Institute of Medical and Biological Engineering in 2010.
      • KEYNOTE: Budd Tucker, PhD
        Stephen A. Wynn Associate Professor of Regenerative Ophthalmology, Director Steven W. Dezii Translational Vision Research Facility, Wynn Institute for Vision Research, Department of Ophthal
        Biography
          Dr. Tucker was born and raised in a small fishing village (population of less than 100) on the northern tip of Newfoundland, Canada. He attended Sir Wilfred Grenfell College in Corner Brook Newfoundland, where in 2001 as an undergraduate student he received his bachelor's degree in Psychology. In 2006 Dr. Tucker went on to complete his Ph.D. degree in neuroscience at Memorial University of Newfoundland's School of Medicine. He subsequently completed a 3-year postdoctoral fellowship at the Schepens Eye Research Institute, Harvard Medical School, where in 2009 under the mentorship of Dr. Michael J. Young he was promoted to the rank of faculty. In 2010 Dr. Tucker joined the Department at the University of Iowa where he is currently an Associate Professor of Ophthalmology and Visual Science. Dr. Tucker has a long-standing interest in the treatment of inherited retinal degenerative diseases such as retinitis pigmentosa (RP), Stargardt disease, Usher Syndrome, and age-related macular degeneration (AMD). His lab is focused on combining state-of-the-art patient-specific stem cell, gene augmentation/genome editing, and tissue engineering based technologies to develop treatments for inherited retinal degenerative blindness.
        • Lay Teng Ang, PhD
          Senior Research Fellow, Genome Institute of Singapore, Singapore
          Biography
            Lay Teng Ang is currently a Visiting Assistant Professor at Stanford University and a Senior Research Fellow at the Genome Institute of Singapore, A*STAR. She received her B.A. (Honours) in Bioengineering from the National University of Singapore and her Ph.D. from the University of Cambridge under an A*STAR Scholarship. Lay Teng has eleven years of research experience and dedicated the past nine years working with human embryonic stem cells (hESCs) and their differentiation towards endodermal and mesodermal cells. Her research has been supported by two ETPL Gap Funding Grants from A*STAR (as PI and co-PI, respectively) and has led to manuscripts in Cell and Cell Stem Cell (as corresponding author). She further led the commercialization effort to position her technology as a research kit, which is now sold worldwide by Thermo Fisher Scientific, Inc. Her ultimate goal is to develop new human cell types for use in regenerative medicine and drug toxicology testing.
          • Randolph Ashton, PhD
            Assistant Professor, Department of Biomedical Engineering and Wisconsin Institute for Discovery- BIONATES, University of Wisconsin-Madison
            Biography
              Randolph S. Ashton received his B.S. from Hampton University in 2002 and Ph.D. from Rensselaer Polytechnic Institute in 2007 in Chemical Engineering. During graduate studies under Prof. Ravi Kane, he researched how engineering biomaterials at the nanoscale could regulate the fate of adult neural stem cells. He continued to pursue his interest in stem cells and tissue engineering at the California Institute for Regenerative Medicine and a NIH postdoctoral fellow at the University of California, Berkeley's Stem Cell Center in the lab of Prof. David Schaffer. In 2011, he was appointed to a faculty position in the Wisconsin Institute for Discovery at the University of Wisconsin-Madison as an Assistant Professor of Biomedical Engineering. The goal of Dr. Ashton's research is to provide novel regenerative therapies to treat CNS diseases and injury. His lab is currently developing scalable protocols to generate region-specific central nervous system tissues from human pluripotent stem cells (hPSCs). They also meld state-of-the-art biomaterial approaches with hPSC-derived neural stem cells to engineer brain and spinal cord tissue models in vitro. Among his awards and honors, Dr. Ashton was named the 2016 Young Faculty Investigator Awardee by the Regenerative Medicine Workshop at Hilton Head, a 2015 Emerging Investigator by Chemical Communications, and a 2013 Rising Star by the Biomedical Engineering Society's Cellular and Molecular Bioengineering Special Interest Group. Also, he has been awarded a Burroughs Wellcome Fund Innovation in Regulatory Science Award, a Draper Technology Innovation Award from the Wisconsin Alumni Research Foundation, and a Basic Research Award from the UW Institute for Clinical & Translational Research. His research is also supported by grants from the NIH and EPA.
            • Jolene Bradford, MLS(ASCP)CM, CCy
              Associate Director, Strategic Collaborations, Biosciences Division, Thermo Fisher Scientific
              Biography
                Jolene Bradford is an Associate Director, Biosciences Division of Thermo Fisher Scientific located in Eugene, Oregon, USA. She joined the company in 2001 and has developed numerous new reagents and assays for the flow cytometry platform.  Well versed in fluorescent assays, Jolene has provided numerous webinars and seminars on the topics, and has been an invited instructor at many flow cytometry training courses and workshops in the US and abroad.   More recently she has been involved in developing acoustic cytometry and instrumentation, and consults on applications. Prior to joining Thermo Fisher Scientific she performed clinical laboratory testing as a specialist in hematology and flow cytometry. In 2014, Jolene earned the Certified Cytometrist International Credential.
              • Pau Sancho Bru, PhD
                IDIBAPS Researcher, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Spain
                Biography
                  Pau Sancho-Bru received his PhD in 2006 from the University of Barcelona. In 2007 he joined the Stem Cell Institute Leuven at the KU Leuven, Belgium as a postdoctoral researcher. In 2012 he was appointed Researcher in IDIBAPS. Pau Sancho-Bru is Principal Investigator at the Liver Injury and Repair Group and Researcher at IDIBAPS. His group is focused on understanding the mechanisms governing liver injury and regeneration and particularly the role of hepatic stellate cells and liver stem/progenitor cells in wound-healing responses. One of the main research interests of his group is developing in vitro systems for disease modeling and assessing the potential of stem cells for biomedical and biotechnological applications.
                • Vijay Chandrasekar, PhD
                  Postdoctoral Fellow, University of Zurich, Switzerland
                  Biography
                    Vijay Chandrasekar was born in the southern part of India called Tamil Nadu. He did his Master studies in microbial gene technology in Madurai Kamaraj University. Following that he worked as a research associate in the premier institute in India called India Institute of Science, where he worked on protein biochemistry and crystallography, where he was successfully involved in structure determination of several viral proteins. For his PhD, Vijay moved to Switzerland in 2010, where he did his doctoral studies in molecular neuroscience on "Characterization of microRNA and transcription factor gene network in cocaine induced neuroplasticity" in the University of Fribourg, Switzerland. His studies established the role of miRNAs in the addiction and neuronal plasticity induced by drugs of abuse in the brain for the very first time and resulted in several highly cited publications. After his PhD, Vijay moved to US to pursue his first postdoctoral fellowship at Columbia University Medical Center under the renowned scientist Prof. Tom Maniatis. during which time, he had his own Helmsley stem cell starter grant in CUMC for his studies on ALS disease using human iPS cells. Vijay worked on two interesting projects (a) HILO-RMCE based generation of iPS cells for studying C9orf72 mutation in ALS; (b) "Identifying the role of miRNAs in astrocyte dependent, non-cell autonomous motor neuron toxicity". He successfully initiated footprint-free reprogramming for in vitro disease modelling using iPS cells. Vijay is currently pursuing his second postdoctoral Scientist position in the Institute of Neuropathology, University Hospital Zurich, Switzerland, working under Prof. Adriano Aguzzi on "Establishing stem cell based systems ES and iPS cells for studying prion mutation in CJD". For the past almost 6 years, he has been working on mouse and human stem cells, both ES and iPS, to derive neurons and other cell lineages for disease modelling, characterization, and drug screening assays using variety of state-of-the-art methods like survival, morphometric measurements, RNAseq, and proteome analysis. Vijay has established the model systems in CUMC and in the University Hospital, Zurich as well as in our collaborative labs in Zurich.
                  • Davide Danovi, PhD
                    Director of HipSci Cell Phenotyping Centre for Stem Cells and Regenerative Medicine, King's College London, United Kingdom
                    Biography
                      Davide Danovi holds an MD from University of Milan and a PhD in Molecular Oncology from the European Institute of Oncology where he demonstrated the causative role of the HdmX protein in human cancer. He completed his postdoctoral training working with Prof. Austin Smith and Dr. Steve Pollard at the University of Cambridge and at University College London where he developed a screening platform to isolate compounds active on human neural stem cells from normal or brain tumour samples. Prior to his current role, he worked as principal scientist at a novel biotechnology company founded to isolate drugs for regenerative medicine using innovative stem cell technologies.
                    • Chris Denning, PhD
                      Professor in Stem Cell Biology, University of Nottingham, United Kingdom
                      Biography
                        Chris Denning is a Professor in Stem Cell Biology, with particular interests in cardiomyocyte (heart cell) differentiation of human embryonic and induced stem cells for use in drug screening and in production of new In vitro models of genetic-based cardiovascular disease. This includes manipulation of the genome using transgenic and nuclease-mediated gene targeting technologies (including Cas9/CRISPR). In parallel, Chris has also focused on optimisation of the culture environment and robotic culture to allow fully automated scale-up and high throughput screening, using high content electrophysiology and imaging.
                      • Faranak Fattahi, PhD
                        PhD candidate, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine
                        Biography
                          Faranak Fattahi has been a graduate student in the laboratory of Dr. Lorenz Studer at Memorial Sloan-Kettering Cancer Center. During her doctoral studies, she focused on development of new strategies to derive lineages of the peripheral nervous system (PNS) from human pluripotent stem cells (hPSCs) and demonstrated their potential for disease modeling, drug discovery, and regenerative medicine. Upon completion of her graduate training, she will join the University of California, San Francisco as a Sandler Faculty Fellow to launch her research program on the application of hPSCs for the study of the human PNS in health and disease.
                        • Joyce Frey-Vasconcells, PhD
                          Regulatory Consultant, Frey-Vasconcells Consulting, LLC
                          Biography
                            Joyce Frey-Vasconcells is considered one of the foremost regulatory experts regarding cell therapies, combination products, gene therapies, tumor vaccines, and tissues and brings extensive regulatory expertise and experience for this unique group of products. Prior to starting FreyVasconcells Consulting, Dr. Frey-Vasconcells served 6 years as a regulatory consultant for Pharmanet working with industry whose mission is to foster product development in the areas of cell therapy, tissues, gene therapy, and tissue engineered products. Prior to joining Pharmanet, she served more than 12 years at the FDA. At FDA, Dr. Frey-Vasconcells was the Deputy Director, Office of Cellular, Tissue, and Gene Therapies (OCTGT) with the Center for Biologics Evaluation and Research (CBER). She was instrumental in developing many of CBER's science and public health policies regarding the regulation of cells, tissues, gene therapies, tumor vaccines, and combination products (tissue engineered products). In 2001, Dr. Frey-Vasconcells was named the Regulatory Expert for Cell Therapies at FDA. She also served on various committees related to combination products, tissue reference group, and HHS committee on tissue engineering to name a few. Since starting Frey-Vasconcells Consulting, Dr. Frey-Vasconcells has continued working with industry on an individual basis and with organizations whose mission is to foster product development in the areas of cell therapy, tissues, gene therapy, and tissue engineered products. She is clearly considered one of the foremost regulatory experts regarding tissues, cell therapies, combination products, gene therapies, and tumor vaccines and is recognized by various state and country stem cell networks as an expert in the regulation of stem cell therapies. She brings extensive regulatory expertise and experience for this unique group of products.
                          • Ben Fryer, PhD
                            Team Leader, Processing/Manufacturing, Heart Regeneration Program, University of Washington School of Medicine, United States
                            Biography
                              Ben Fryer is the team leader for CMC-Cell Manufacturing and Processing at the University of Washington School of Medicine's Heart Regeneration Program (HRP). Ben joined the HRP in January 2015. The program was started by Chuck Murry and is currently in pre-clinical development of a therapy to treat heart disease using cardiomyocytes generated from hES cells. Prior to joining HRP, Ben worked at Janssen R&D's internal diabetes venture (BetaLogics) from 2006 to 2014. BetaLogics' mission was to treat insulin-dependent diabetes with a combination islet-like tissue product generated from hES cells and delivered via an immune-isolation device. Ben managed an internal research team and several external partnerships dedicated to finding a defined and scalable method to manufacture pancreatic beta islets for the treatment and cure of diabetes. Ben earned a BA from Colorado College and his PhD in pharmacology from the University of Pennsylvania. As a post-doc he studied Hypoxia Inducible Factor in cancer and stem cell development in the Howard Hughes Laboratory of M. Celeste Simon at the University of Pennsylvania. Prior to graduate school he worked for several small biotech/pharmaceutical firms in the Denver-Boulder area supporting discovery research and pre-clinical and clinical development of small and large molecule therapies for cancer. Ben is an inventor on several pending patents for Janssen/Johnson&Johnson, including stirred tank bioreactor based suspension expansion and differentiation processes and a product currently marketed by Thermo-Fisher™ as Nunc™ Nunclon™Vita.
                            • Jing He, PhD 何静 博士
                              Technical Application Scientist, Cell Biology, Life Sciences Solutions, Thermo Fisher Scientific 赛默飞生命科学产品与服务集团技术支持专家,从事细胞培养、蛋白表达以及转染相关应用的技术支持
                              Biography
                                From July 2012 to the present, Technical Application Scientist for cell culture, protein expression, and transfection-related products at Thermo Fisher Scientific. Dr. He received her PhD in Biochemistry and Molecular Biology from the National Institute of Biological Sciences (NIBS, Beijing), The main research areas of her PhD studies were stem cell-reprogramming and embryonic development.
                              • William Hendriks, PhD
                                Instructor in Neurology, MGH Collaborative Center for XDP, Department of Neurology, Massachusetts General Hospital, Harvard Medical School
                                Biography
                                  After receiving his PhD in Neuroscience at the VU University Amsterdam in the Netherlands in 2008, Dr. Hendriks joined the lab of Dr. Paola Arlotta at the Center for Regenerative Medicine of Massachusetts General Hospital (MGH) in Boston to study neuronal development focusing on neuronal differentiation of human pluripotent stem cells. In 2011, Dr. Hendriks joined the Harvard Stem Cell Institute (HSCI) iPS Core facility with Dr. Chad Cowan at Harvard University in Cambridge, where initially he worked on developing and implementing foot-print free somatic cell iPSC reprogramming methods. Dr. Hendriks also initiated and managed the hPSC genome editing service for 2 years at HSCI before moving to his current position as a Harvard Medical School Instructor in Neurology at the MGH Collaborative Center for X-Linked Dystonia Parkinsonism.
                                • Lachlan Jolly, PhD
                                  ARC DECRA Fellow, Neurogenetics Research Program, School of Medicine, Faculty of Health Sciences, The University of Adelaide, Australia
                                  Biography
                                    Jolly completed his PhD at the University of Adelaide, South Australia, in 2010 during which he applied neural differentiation of embryonic stem cells to study the earliest stages of brain development. He next joined the Neurogenetics Research Program headed by Professor Jozef Gecz for post-doctoral training at the Women's and Children's Hospital in Adelaide (SA Pathology). His application of various neural cell culture models of brain development resulted in the discovery of several new genetic causes of neurodevelopmental disorders. Dr. Jolly now leads his own research group at the University of Adelaide, focussing on the roles of the Nonsense Mediated mRNA Decay (NMD) pathway, and the genes USP9X, HCFC1, and PCDH19 in normal and pathological processes of brain development and function. He is currently an Australian Research Council DECRA Fellow.
                                  • David Kuninger
                                    Associate Director and Group Leader, Thermo Fisher Scientific
                                    Biography
                                      Dr. Kuninger leads research, development and commercialization of next generation culture systems for pluripotent stem cell culture, differentiation, neurobiology and non-hepatic primary cell biology at Thermo Fisher Scientific in the Cell Biology business based in Frederick MD. His teams support numerous portfolios and have launched over 15 new products spanning stem cell culture & cryopreservation, differentiation (endo-, ecto- and meso-dermal lineages) and neurobiology, leading to more than 25M in revenue over the last 3 years. David is a seasoned scientist and manager, experienced in media formulation & optimization as well as with sophisticated experimental design and data modeling tools applied to cell imaging and functional analysis endpoints as well as 2D and 3D culture models. Expertise in GLP/GMP compliance, technical transfer and scale up, verification and validation processes. Prior to starting at Thermo Fisher Scientific (legacy Invitrogen) in 2007 as Staff Scientist, he joined Oregon Health Sciences University (OHSU) as a Postdoctoral Fellow investigating the actions of insulin-like growth factors (IGFs) in the lab of Dr. Peter Rotwein, subsequently joining the faculty in the Department of Biochemistry at OHSU as a Research Instructor. He completed is PhD in Biochemistry and Genetics University of Texas Medical Branch, Galveston, Texas in the laboratory of Dr. John Papaconstatinou and has a B.S. in Chemistry from the University of Oregon in Eugene OR.
                                    • Leo Kurian, PhD
                                      Independent Group Leader CECAD - Cluster of Excellence, Institute for Neurophysiology & Center for Molecular Medicine (CMMC), University of Cologne, Germany
                                      Biography
                                        Leo Kurian completed his basic education in chemistry followed by a Master's degree in biotechnology in India. He obtained his PhD in genetics from the University of Cologne. He spent his post-doctoral years in the Belmonte lab at the Salk Institute and in the Yeo lab at UCSD (both in San Diego, California), where he established stem cell-based models to study programming and reprogramming of cell-fate decisions. In 2014, he established an independent group, supported by the NRW Stem Cell Network, to study the regulatory basis of cardiac development, aging, and regeneration at the University of Cologne.
                                      • Stephen Lin, PhD
                                        Senior Science Officer, Strategic Infrastructure, California Institute for Regenerative Medicine
                                        Biography
                                          Stephen Lin is a senior science officer at California's stem cell agency, CIRM. He joined the Agency in 2015 to oversee its $32M initiative to create a repository of iPSCs from up to 3,000 individuals, covering both genetically complex and rare diseases, as well as a $40M genomics initiative that applies cutting edge genomics and bioinformatics approaches to stem cell research and therapeutic development. He is also the program lead on a newly created $15M preclinical research organization termed the Translating Center that focuses on preparing stem cell therapy candidates for clinical trials through support with process development, safety/toxicity studies, and manufacturing. From 2012 he had been a staff scientist and team lead at Thermo Fisher Scientific (formerly Life Technologies). Prior to that he was a scientist since 2006 at StemCells, Inc. of California in the area of liver cell therapeutics. Dr. Lin received his PhD from Washington University in St. Louis in 2002 under Jeffrey Gordon and did his postdoctoral research at Harvard University under Stanley Korsmeyer.
                                        • Willie Lin, PhD
                                          Chief Executive Officer, Meridigen Biotech Co., Ltd., Taiwan
                                          Biography
                                            Dr. Willie Lin received his Bachelor of science in Animal Sciences from Tunghai University in Taiwan followed by a doctorate in Biochemistry from Kansas State University in the USA. He is currently serving as the Chief Executive Officer of Meridigen Biotech based in Taiwan. Dr. Lin's professional experience has included: Adjunct Associate Professor of the Master Program in Technology Management at Fu Jen Catholic University; Chairman and President of Microbio Co., Ltd and Fountain Biopharma, Inc; President and Chief Operating Officer at UniMed Venture Management, Inc; Associate Vice President of the Strategy and Planning Department at China Chemical and Pharmaceutical Co.; and Associate Vice President in the Overseas Business Department for the China Development Industrial Bank.
                                          • Jeanne Loring, PhD
                                            Principal Investigator, The Scripps Research Institute, Center for Regenerative Medicine
                                            Biography
                                              Jeanne Loring is Professor and the founding Director of the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla. Her research team focuses on large-scale genomic and epigenetic analysis of human pluripotent stem cells (hPSCs), with the goal of ensuring their effectiveness and safety for cell therapy. Her lab is developing stem cell-based therapies for Parkinson's disease and multiple sclerosis, and investigates the underlying causes of autism using patient-specific stem cells. With the San Diego Zoo, her lab is developing a "zoo" of induced pluripotent stem cells from endangered species to aid in their conservation. Dr. Loring serves on many scientific and bioethics advisory boards, including the Merck KGaA Bioethics Advisory Panel (Germany) and the scientific advisory boards for Genea Biocells, Inc. (Australia), Kadimastem, Inc. (Israel), Coriell's NIGMS Human Genetic Cell Repository, the National Center for Biomedical Glycomics, the NIMH Repository & Genomics Resource (Rutgers), and the Heart Regeneration Program. She was a member of the Panel on Global Assessment of Stem Cell Engineering (NSF, NIST, and NIH) and the Panel on Review of the Material Measurement Laboratory at NIST (The National Academies). She is frequently quoted in major newspapers, appears on television and in documentary features, and gives many public lectures about science and society. She is particularly concerned with the dangers of unregulated stem cell treatments in the US and other countries ("stem cell tourism").
                                            • Chad MacArthur
                                              R&D Scientist, Thermo Fisher Scientific
                                              Biography
                                                Chad MacArthur is an R&D scientist with Thermo Fisher Scientific. Chad joined Invitrogen in 2007, and in the past 9 years his work has focused on many different areas of the pluripotent stem cell workflow, including stem cell engineering, media development, stem cell characterization, and reprogramming systems. Prior to working for Thermo Fisher Scientific, Chad received his M.Sc. in Biochemistry from California State University, Long Beach, where his research focused on enzyme inhibitors and kinetics, drug discovery, and cell biology
                                              • Anish Sen Majumbar, PhD
                                                CSO & Executive VP, Stempeutics Research, India
                                                Biography
                                                  Dr. Anish S Majumdar is the Chief Scientific Officer & Executive VP of Stempeutics Research in Bangalore, India, since 2010. He has been working in the field of stem-cell based research and product development for more than 20 years. Dr. Majumdar received his Ph.D. in Biochemistry/Immunology from the University of Calcutta, India. He pursued postdoctoral research at the University of Pennsylvania and subsequently joined Stanford University as a Research Scientist. He has worked at Indian and US based biopharmaceutical/cell therapy companies in various positions: Among the US companies are BD Biosciences, Aventis, and Geron Corporation. Dr. Majumdar joined Geron Corporation in 1998 and became Senior Director, Cell Therapy Research in 2005. In 2007, he relocated to India where he joined Reliance Life Sciences, Mumbai as Vice President of Stem Cell Research & Regenerative Medicine. He has published nearly 80 research articles, reviews, and book chapters in acclaimed journals and is a co-inventor of 70+ international patents. Dr. Majumdar's research expertise spans from the biology, immunology and therapeutic applications of mesenchymal stem cells (MSC), differentiation of human embryonic stem cells (ESC), dendritic cells, and T-cells for developing anti-cancer vaccines. Currently, the use of MSCs for various therapeutic applications in regenerative medicine is his focus at Stempeutics, and has met with strong success. He is a member of the Industry Committee of the ISSCR, Federation of Indian Chamber of Commerce, and Industry (FICCI) for the Biotechnology Chapter as a stem cell expert. In 2013, Dr. Majumdar was elected as Vice President for Asia region of the ISCT. In this position, he represents India and Asia, and he is committed to promoting the use of stem cell based therapeutics for diseases with unmet or urgent medical need.
                                                • Michael Mendicino, PhD
                                                  Owner, Chief Consultant & Advisor, Hybrid Concepts International
                                                  Biography
                                                    Michael Mendicino established Hybrid Concepts International (HCI) as a consultancy and advisory firm in the niche and emerging fields of cell therapy, gene and gene-modified cell therapies, other regenerative medicines, tissue engineering, and cell-based drug discovery. Michael also previously worked at four biotech companies, and/or consulted, all within the aforementioned fields, covering areas such as CMC and strategic regulatory affairs, R & D, commercial, and product & technology due diligence activities. During his FDA appointment, Michael worked in the Office of the Commissioner with the regulatory science & innovation team. He also worked in the Office of Cellular, Tissue & Gene Therapies (OCTGT), where he performed regulatory submission review and provided guidance to sponsors for cell therapy products, devices and combination products. Major accomplishments include world's first IND trend projects (published in Cell Stem Cell and Nature Biotechnology), and a semi-finalist ranking for the Kauffman Fellowship (venture/investment). Michael is a representative on multiple Alliance for Regenerative Medicine (ARM) and International Society for Cellular Therapy (ISCT) committees (including Co-Chair of ARM's Science & Technology Committee, both ARM and ISCT Regulatory committees, and the ISCT Commercialization committee and Process & Product Development subcommittee). Michael is currently a member of the Board of Directors, first President and a key leader for the nonprofit Standards Coordinating Body (SCB), which is now a public-private partnership.
                                                  • Nuria Montserrat, PhD
                                                    Junior Group Leader, Pluripotent Stem Cells and Activation of Endogenous Tissue Programs for Organ Regeneration, The Institute for Bioengineering of Catalonia (IBEC), Spain
                                                    Biography
                                                      Dr. Montserrat undergraduate training in Spain, Switzerland, and France, and postgraduate training in Spain and the US. Her research career started early in 2008 at the Center of Regenerative Medicine of Barcelona (CMRB), under the direction of Dr. Izpisua Belmonte. There, she led and participated different projects involving the generation and banking of iPS lines, and set up safe strategies using specific transcription factors determinant for lineage specification (GATA3) for somatic reprogramming. She also collaborated in other projects aimed to characterize the genomic integrity of human iPSCs as well as in the differentiation of iPSCs towards germ cells, neural cells, endothelial cells, retinal cells and blood cells. In the same manner, Dr. Montserrat participated in the generation of platforms for the study of disease progression and compound screening for therapy by means of human iPSCs. Moreover, her interest in organ regeneration provided new knowledge for the generation, for the first time, of kidney organoids, suitable for the study of hiPSCs differentiation towards renal lineages and compound screening for therapeutic purposes. Recently she has identified, for the first time, how the reactivation of endogenous regenerative programs that are dormant in adult murine heart can be reactivated and elicit heart regeneration. Dr. Montserrat research also benefits from the use of bioengineering strategies (organ decellularization and 3 D bioprinting) for human pluripotent stem cells differentiation, with specific focus in heart and kidney. The European Research Council (ERC-ERC Starting Grant), and Spanish national programs and networks support Dr. Montserrats research. Currently, Dr. Montserrat is group leader at the Institute of Bioengineering of Catalonia (IBEC), in Barcelona. Her research is focused on the study of molecular programs sustaining reprogramming and differentiation, with special focus on mesodermal-derived tissues suchas kidney and heart.
                                                    • Lise Munsie, PhD
                                                      Development Scientist, CCRM
                                                      Biography
                                                        Dr. Lise Munsie currently holds the position of Development Scientist at CCRM. She obtained her PhD in the department of Biochemistry and Biomedical Science at McMaster University and held a 3-year postdoctoral fellowship at the University of British Columbia (UBC), jointly between the department of Medical Genetics and the department of Neuroscience. At CCRM, a leader in developing and commercializing regenerative medicine technologies, and cell and gene therapies, Lise oversees a variety of projects related to iPSC derivation, directed differentiation and genome engineering.
                                                      • Rhonda Newman, PhD
                                                        Senior Staff Scientist, Cell Biology, Thermo Fisher Scientific
                                                        Biography
                                                          Dr. Newman joined Thermo Fisher Scientific in 2010 and is currently working on next-generation stem cell culture and differentiation systems, enabling researchers to efficiently culture, expand, cryopreserve, and differentiate their stem cells to various cellular lineages. She received her PhD at the University of Iowa working in the lab of Dr. Madeline Shea. Subsequently, she completed postdoctoral training in the lab of Dr. Ken Prehoda at the University of Oregon, studying the role of intramolecular interactions in regulating cell signaling cascades in the process of asymmetric stem cell division.
                                                        • Cory Nicholas, PhD
                                                          Co-Founder and Chief Scientific Officer, Neurona Therapeutics, Assistant Professor, Adjunct, University of California, San Francisco, United States
                                                          Biography
                                                            Dr. Cory Nicholas is Chief Scientific Officer at Neurona Therapeutics. Prior to launching Neurona, Dr. Nicholas was a faculty member in the Department of Neurology at the University of California, San Francisco, where his research program was focused on elucidating the ontogeny of human cortical interneurons. Using embryonic brain development as a blueprint, Dr. Nicholas pioneered methods to derive interneuron precursors from human pluripotent stem cells and developed transplantation cell-based therapies for multiple animal models of neurological disease. He maintains an adjunct faculty appointment at the university. Dr. Nicholas's post-doctoral studies were conducted at UCSF. His pre-doctoral work at both UCSF and Stanford University investigated germ cell development from both primordial germline and pluripotent stem cells. He received his Bachelor's degree from the University of California, Berkeley. Prior to his interest in stem cell and developmental biology, Dr. Nicholas was a member of the discovery research team at Sugen, Inc.
                                                          • Michael O'Connor, PhD
                                                            Director, Molecular Medicine Research Group, Western Sydney University, Australia, Senior Lecturer, School of Medicine, Western Sydney University, Australia Honorary Senior Lecturer, Save S
                                                            Biography
                                                              Michael uses human pluripotent cells to model macular degeneration and cataract. He received his PhD from the University of Sydney in 2005, regenerating and characterising functional ocular lenses in vitro. During postdoctoral studies in Vancouver, Canada, he identified genes related to pluripotency and played a key role in the commercial development of mTeSR1 and TeSR2 with Stem Cell Technologies. As the current President of the Australasian Society for Stem Cell Research he has developed a touring stem cell art exhibition, seen by over 1 million people, that stimulates public discussion on emerging stem cell therapies.
                                                            • Hideyuki Okano, MD, PhD
                                                              Dean, Professor, Department of Physiology, Keio University School of Medicine, Japan
                                                              Biography
                                                                Professor Hideyuki Okano is Dean of Keio University School of Medicine and Team Leader of Laboratory for Marmoset Neural Architecture, Brain Science Institute RIKEN. In addition, Dr. Okano holds important posts, including University of New South Wales Visiting Professor (Since 2009), University of Queensland Honorary Professor in the Queensland Brain Institute (Since 2008), and Professor of Department of Physiology, Keio University School of Medicine (Since 2001). In the past he served as Professor of Osaka University Graduate School of Medicine (Department of Neuroscience, 1997-2001) and Professor of University of Tsukuba (Department of Molecular Neurobiology, Institute of Basic Medical Sciences, 1994-1997). He also did research at the University ofTokyo and The Johns Hopkins University School of Medicine as instructor. Dr. Okano has been the recipient of numerous awards, most recently including the Molecular Brain Award (2016), Balz Award (2014) and the Medal with Purple Ribbon (from the Emperor of Japan, 2009). His scientific research area is basic neuroscience, stem cell, and regenerative medicine including iPSC, NSC, and clinical applications for spinal cord injury.
                                                              • Alice Pébay, PhD
                                                                Associate Professor, ARC Future Fellow, Head, Neuroregeneration Research Unit, Centre for Eye Research Australia, University of Melbourne
                                                                Biography
                                                                  Dr. Pébay is an Australian Research Council Future Fellow. She obtained her PhD in Neurosciences from the University of Paris VI in 2001 and subsequently joined Professor Martin Pera at Monash University to undertake research on human embryonic stem cells (hESCs). She then continued her research in this area at the University of Melbourne where she commenced in 2007. Since 2012, Dr.Pébay has been appointed to both the Centre for Eye Research Australia and The University of Melbourne. More specifically, Dr. Pébay heads research projects on the identification of signaling mechanisms involved in the maintenance of pluripotency, neural differentiation and more recently cardiac and ocular differentiation of pluripotent stem cells and diseased iPSCs. Her long-term research goal is the establishment of well characterized and efficient protocols for maintenance and differentiation of pluripotent stem cells, suitable for drug screening.
                                                                • Rene Quintanilla Jr.
                                                                  R&D Scientist, Cell Biology, Thermo Fisher Scientific
                                                                  Biography
                                                                    Rene has been a Research and Development scientist for the last 8 years at Thermo Fisher Scientific where his expertise extends to gene delivery methods, iPSC reprogramming, and cellular/molecular characterizations of pluripotent stem cells. He helped develop the Gibco PSC Training Course and has authored many peer reviewed articles and book chapters on Pluripotent Stem Cell characterization. Prior to joining Thermo Fisher Scientific, he was involved in over 6 years of professional basic research in academia in the fields of enzymology, stem cell biochemistry and neurogenesis, molecular genomics, and kinase biochemistry.
                                                                  • Morrie Ruffin, PhD
                                                                    Managing Director, Alliance for Regenerative Medicine
                                                                    Biography
                                                                      Morrie Ruffin has more than 20 years of experience in the biotech and healthcare industries. Morrie is the co-founder and managing director of the Alliance for Regenerative Medicine (ARM). He is also the managing partner of Adjuvant Partners, a life sciences advisory practice working with product developers and major medical centers advancing programs in cell and gene therapy. Prior to joining Adjuvant in 2008, he was the Chief Executive Officer of LifeTech Innovations. From 1994-2006, Dr. Ruffin was Executive Vice President of Capital Formation and Business Development at the Biotechnology Industry Organization (BIO), the largest trade organization representing the biotech and drug development industries. Joining BIO in 1994 as one of its original employees, Dr. Ruffin was responsible for building the organization's global business development and investor outreach programs focused on helping companies raise capital and identify strategic partnering and licensing opportunities. This BIO business development franchise is now the largest in the world, with operations in the US, Europe, and Japan. In addition to his business development work at BIO, Dr. Ruffin was responsible for leading the industry's capital formation advocacy efforts with a focus on economic incentives to promote investment in early stage biotech and med-tech businesses. He is also a founder and board member of the Interoperable Informatics Infrastructure Consortium (I3C), an international standards setting body for the bioinformatics industry. Prior to joining BIO, Dr. Ruffin worked for US Senator Arlen Specter for five years as his senior legislative assistant. Prior to that, he spent approximately five years working in varying capacities, including policy analyst at Systems Planning Corporation International and the Center for Strategic and International Studies. Dr. Ruffin received his MA in International Studies & Economics from the Johns Hopkins School for Advanced International Studies (SAIS) and his BA from the University of Virginia.
                                                                    • Karim Si-Tayeb, PhD
                                                                      Young Investigator, l'institut du thorax INSERM, France
                                                                      Biography
                                                                        After achieving his PhD in Bordeaux under the direction of Dr. Jean Rosenbaum, Dr. Si-Tayeb joined the research team of Professor Stephen Duncan at the Medical College of Wisconsin, Milwaukee, WI. Together, they developed a strategy to direct patient-derived hiPS cells to become liver cells and study metabolic diseases, including familial hypercholesterolemia. Back in France, and after a short passage in Paris, Dr. Si-Tayeb joined the "institut du thorax" in Nantes in order to work more specifically on PCSK9 together with Prof Bertrand Cariou, an MD-PhD who specializes in endocrinology who participated in clinical trials on PCSK9 inhibition and Dr Cédric Le May specialized in lipid metabolism. Dr. Si-Tayeb and his team showed how it is possible to isolate cells from urine samples, amplify them, reprogram them into hiPS cells and then direct them to become liver cells. Starting with urine samples of patients from the Nantes area, they showed that it was possible to model the effects of PCSK9 mutations on LDL uptake in a petri dish.
                                                                      • Kelli Tanzella, PhD
                                                                        Sr. Director Global Regulatory Affairs, Clinical, & Compliance for Life Sciences Solution Group (LSG), Thermo Fisher Scientific
                                                                        Biography
                                                                          Kelli L. Tanzella, Ph.D. Sr. Director Global Regulatory Affairs, Clinical, & Compliance for Life Sciences Solution Group (LSG) at Thermo Fisher Scientific, Inc., has over 20 years' experience in quality and regulatory requirements in both the pharmaceutical and medical device industries. She has been with Life Technologies/Thermo Fisher Scientific for 14 years in Regulatory Affairs with increasing levels of responsibility. Her expertise includes quality systems management, clinical trial monitoring, and the filing of U.S. and foreign regulatory submissions. She leads the global regulatory team within the Life Sciences Group at Thermo Fisher and provides functional leadership to regional regulatory teams outside of this Group to enable regulatory pathways in the applied markets. Kelli received a Bachelors of Science in Biology from Niagara University and went on to receive a Masters of Science and Doctorate degree in Health Services Administration with a focus on government health policy.
                                                                        • Nick Timmins, PhD
                                                                          Vice President, Technology and Director, BridGE at CCRM, Canada
                                                                          Biography
                                                                            Nick is VP, Technology, and Director, BridGE at CCRM. A bioprocess engineering by training, his career has focused on the development of manufacturing process for cellular therapies. Following undergraduate studies in New Zealand he gained his PhD in Australia, did a post-doc in Switzerland, returned to Australia as a research Team Leader, and in 2011 relocated to Canada to join CCRM.
                                                                          • Bernie Tuch, PhD
                                                                            Director, NSW Stem Cell Network, Australia
                                                                            Biography
                                                                              Dr. Bernie Tuch is Director of the NSW Stem Cell Network and a Professor of Medicine at both The University of Sydney and Monash Universities. He is involved in cutting-edge research with clinical applications, looking at novel ways of achieving positive outcomes. Attempts to examine the safety and efficacy of novel interventions have been through phase 1b/2a clinical trials, including the use of human fetal pancreas, and more recently encapsulated human islets, as a therapy for type 1 diabetes. His former research group was responsible for the creation of the first human embryonic stem cell lines at an Australian public hospital. Over the past few years he and his colleagues have grappled with the issue of trying to move the stem cell field forwards expeditiously in humans with interventions, many of which are unproven.
                                                                            • Hans-Dieter Volk, MD
                                                                              Chairman, Institute for Med. Immunology & Berlin-Brandenburg Center for Regenerative Therapies (BCRT) & Dept. Immunology, Labor Berlin Vivantes, Charité GmbH Charité-Universitätsmedizin, Berl
                                                                              Biography
                                                                                Hans-Dieter Volk, MD, is Professor of Immunology and head of the both the Institute of Medical Immunology, Charité Berlin and Berlin-Brandenburg Center for Regenerative Therapies (BCRT) as well as deputy spokesman of the Berlin-Brandenburg School for Regenerative Therapies (BSRT) (all Berlin, Germany). In addition, he is scientific head of the Division of Immunology of the Labor Berlin Charité Vivantes GmbH, Berlin. His focus lies in implementation of new concepts in diagnosis and therapy of immunological diseases. Dr. Volk is an expert in coordinating and conducting clinical trials by biomarker development, monitoring new cell therapies, performing proof-of-concept and investigator-initiated trials (all phase I/II). He has been co-editor/editorial board member of several high-impact journals and board member of several scientific medicine societies (e.g., German Society Immunology, German Society Sepsis).
                                                                              • Dustin Wakeman, PhD
                                                                                Senior Research Scientist, Regenerative Medicine RxGen, Inc.
                                                                                Biography
                                                                                  Dr. Wakeman's primary research goals are directed at determining the long-term value of stem cell-based therapeutics for regenerative medicine. His past work using dopamine neurons derived from pluripotent stem cells, both human embryonic stem cells and induced pluripotent stem cells (iPSC), as a cell based strategy for dopamine replacement in animal models of Parkinson's disease has consistently supported therapeutic value moving toward the clinic. Dr. Wakeman recently joined RxGen, Inc., a translational therapeutics and disease modeling company, where he is applying his expertise and experience in regenerative medicine to bridge the translational research gap using primate models of human disease. Dr. Wakeman also holds an Adjunct Assistant Professor position in the Department of Psychiatry at Yale School of Medicine.
                                                                                • Michael Werner
                                                                                  Partner, Holland & Knight
                                                                                  Biography
                                                                                    Michael Werner is a partner in Holland & Knight's Washington, DC, office and co-chair of the firm's Healthcare & Life Sciences Industry Team. He has almost three decades of healthcare law, regulatory, reimbursement, and lobbying experience in Washington. He focuses on issues affecting biotechnology and pharmaceutical companies, medical research and research institutions, physicians and patients. His specific areas of knowledge include FDA regulations regarding drug/biological product review, approval, and distribution; regulation of cell therapy, gene therapy, tissue engineering and regenerative medicine products; IRB review, informed consent, and other clinical trial issues; regulation and reimbursement of biosimilars; Medicare reimbursement strategy and issues; and conflicts of interest and other bioethics issues arising from research and uses of new technologies. Mr. Werner is the co-founder and Executive Director of the Alliance for Regenerative Medicine, a Washington, DC-based organization comprised of over 240 member companies, clinical centers, patient advocacy groups and other organizations worldwide whose mission is to advocate for regulatory and reimbursement policies that will advance regenerative medicine research and product development. Before joining Holland & Knight, he was president of The Werner Group, a Washington, DC-based firm that provided lobbying, regulatory, and bioethics consulting services for biotechnology and pharmaceutical companies, physicians, health plans, investors, and patient advocacy groups. Prior to founding The Werner Group, he was chief of policy for the Biotechnology Industry Organization (BIO), representing over 1,000 biotechnology companies in the U.S. and other countries. In that role, he was responsible for virtually all major issues affecting biotech companies including: drug/biologic evaluation and review by FDA; CMS policies and reimbursement, Medicare, intellectual property, stem cell research and bioethics issues. Mr. Werner was senior healthcare advisor to U.S. Senate Majority Leader George Mitchell, a congressional investigator for the U.S. Senate Special Committee on Aging and senior advisor to Maryland Governor William Donald Schaefer. Mr. Werner is a frequent media commentator and has appeared in The Wall Street Journal, Science, Scientific American, and The Washington Post. In 2013 and 2014, he was named one of the Top 50 Global Stem Cell Influencers by Total BioPharma. He was also recently named to the US National Academies of Science, Engineering and Medicine's Forum on Regenerative Medicine. He is a heavily sought-after speaker for meetings and conferences, and the author of over 50 published articles. Michael is co-author of the Bloomberg BNA portfolio series "Life Sciences Compliance: a Pre-market and Post-market Portfolio". His article "Don't Edit the Human Germ Line" appeared in the March 2015 issue of Nature.
                                                                                  • Nektaria Andronikou
                                                                                    Staff Scientist, Cell Biology, Thermo Fisher Scientific
                                                                                    Biography
                                                                                      Nektaria Andronikou joined the research and development team at Thermo Fisher Scientific in 2010 working within the R&D transfection delivery team. She is currently involved in the development of delivery technologies targeting relevant cellular models and in vivo systems that will enable the use of exciting new technologies, such as CRISPR, messengerRNA and cell therapy. Nektaria began her professional career at ISIS Pharmaceuticals, as a research associate for the Cardiovascular Drug Discovery program, screening numerous pre-clinical targets that led to the discovery of the now FDA approved antisense drug, Kynamro. She received a Bachelor of Science in Biochemistry with a minor in Cellular and Molecular Biology from UCSD.
                                                                                    Scheduled Live Chats

                                                                                    All Scheduled Live Chats with our stem cell experts were logged and are now available on-demand as transcripts. Log into the virtual environment to access.

                                                                                    LIVE CHAT: Stem cell characterization and analysis
                                                                                    Rene Quintanilla and Maha Sridharan
                                                                                    Characterizing and analyzing cells may be one of the most important steps in stem cell culture. Talk about your techniques and hear our expert opinions about different approaches to creating a complete characterization profile for your cells.

                                                                                    LIVE CHAT: Reprogramming
                                                                                    Uma Lakshmipathy and Chad MacArthur
                                                                                    Find out how our experts have evaluated different reprogramming methodologies and which ones they recommend for your cell type.

                                                                                    LIVE CHAT: Clinical trials/logistics
                                                                                    Vin Sing and Matthew Frazzetta
                                                                                    In need of practical advice on designing a cell-based clinical trial logistics strategy? Ask our knowledgeable scientists about the essential elements of material handling to control costs and ensure success.

                                                                                    LIVE CHAT: Differentiation
                                                                                    David Kuninger and Soo Shin
                                                                                    Discuss the challenges associated with hPSC differentiation and neural, cardiac, and hepatic cell model development.

                                                                                    LIVE CHAT: PSC culture
                                                                                    Rhonda Newman and Lauren Sangenario
                                                                                    Many different PSC culture media are available and range from feeder-dependent to feeder-free, and from many animal-derived components to more xeno-free formulations. Our experts have tried them all. Learn how they compare and recommend different media for your applications.

                                                                                    LIVE CHAT: Regulatory
                                                                                    Kasey Kime and Sandy Kuligowski
                                                                                    As the field of clinical research grows, it is more important than ever to pay close attention to raw materials, manufacturing processes, and analytics used in developing potential cell therapies. Ask our team your questions about moving from bench to clinic, and let them share their global experience with you.    

                                                                                    LIVE CHAT: Gene editing
                                                                                    Erik Willems and Jason Carte
                                                                                    Ask our experts about which gene editing tools work best for different cell lines and how to improve editing outcomes, or engage in a discussion about how gene editing in stem cells may change the future of modern medicine.

                                                                                    Education

                                                                                    What educational opportunities are available on-demand?

                                                                                    Event certification
                                                                                    Participate in the following activities within the virtual environment to earn an event certificate of completion and free T-shirt**.  Event certification is only available until May 17, 2017.

                                                                                    • View two presentations of your choice
                                                                                    • Submit a question to one of our experts via a scheduled chat, a presentation, or a booth
                                                                                    • Visit a booth in the Exhibit Hall
                                                                                    • Visit a virtual training lab
                                                                                    • Complete a short survey


                                                                                    PSC training with our experts
                                                                                    Expand your stem cell knowledge with a variety of training presentations from our stem cell experts. Topics include PSC culture, reprogramming, characterization, and transfection. Training presentations are available on-demand and can be accessed at your convenience.

                                                                                    Virtual training
                                                                                    Test your knowledge and sharpen your stem cell skills in one of our virtual training labs. Topics include pluripotent stem cell culture, basic cell culture, transfection and protein expression.

                                                                                     

                                                                                    *No purchase necessary. This promotion is available only to qualifying attendees of 24 Hours of Stem Cells who earned an event certification. Qualifying attendees will receive a T-shirt. Qualifying attendees in China will receive a LED table lamp. Free T-shirt or lamp is available to eligible participants who submit a request no later than May 17, 2017 or until gift supplies are depleted, whichever comes first. The estimated value of the T-shirt is $12.00 USD, and the estimated value of the lamp is $15.00 USD. One free gift per person. Life Technologies will fulfill T-shirt size requests whenever possible, but reserves the right to substitute sizes if necessary. Healthcare professionals may not participate in this promotion. Government Officials may not participate in this promotion. The term Government Official includes anyone who acts in an official capacity for or on behalf of a government entity, department, or agency. By registering, you warrant that you are not prohibited by employment, contract, or law from accepting a gift from Life Technologies. Offer void where prohibited, licensed, or restricted by federal, state, provincial, or local laws or regulation or agency/institutional policy. Other restrictions may apply.
                                                                                     

                                                                                    Sponsored By

                                                                                    For information on becoming a sponsor or exhibitor, please click here.


                                                                                    Help

                                                                                    General LabRoots Questions

                                                                                    For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                                                                    Contact us

                                                                                    Virtual Events and Webinars

                                                                                    Supported Configurations

                                                                                    • Operating System Internet Explorer Firefox Chrome Safari
                                                                                      Vista IE8+ FF10+ Chrome15+
                                                                                      Windows 7 IE8+ FF10+ Chrome15+
                                                                                      Windows 8 IE10 FF10+ Chrome15+
                                                                                      Mac OS X   FF10+ Chrome15+ Safari5.1+
                                                                                    • Cookie settings: session cookies enabled
                                                                                    • Browser configuration must have JavaScript enabled
                                                                                    • Adobe Flash player 10.2 or later

                                                                                    To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                                                                    Internet Connection

                                                                                    • A minimum of 100Kbps is recommended for audio-only events
                                                                                    • A minimum of 300Kbps is recommended for speaker on-video events

                                                                                    Computer Equipment

                                                                                    • Screen Resolution: Minimum 1024x768
                                                                                    • Video Card: 65,000 colors minimum
                                                                                    • Sound card and speakers (or headphones) for hearing webcast in full format
                                                                                    • Audio Card: 16-bit minimum
                                                                                    • RAM: 512MB of free RAM

                                                                                    Firewall Protocol

                                                                                    • HTTP on port 80 or HTTPS on port 443
                                                                                    • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                                                                    • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                                                                    Work-At-Home Attendees

                                                                                    • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                                                                    For A Seamless Experience

                                                                                    When using a mobile device, FREE Mobile Apps are available:

                                                                                    - For viewing Webinars:

                                                                                    - For viewing Virtual Events

                                                                                    Attendee Guide

                                                                                    • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                                                                    Virtual Event and Webinar Support:

                                                                                    Continuing Education (CME/CE) Support

                                                                                    Loading Comments...
                                                                                    Show Resources